Could a delayed booster still protect against HPV?

NCT ID NCT02568566

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study is testing whether giving the HPV vaccine (Gardasil 9) on a different schedule still works well in healthy 9-11 year olds. The standard schedule uses two or three doses, but this study gives a first dose and then a booster later. Researchers will measure antibody levels over two years to see if protection lasts. The goal is to find a simpler schedule that might be easier for families to complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV vaccine (Gardasil 9)
What this could lead to
If successful, this could support a simpler, delayed-booster schedule for the HPV vaccine, making it easier to complete.
What could go wrong
This is a small, early-phase study (Phase 2) with no control group. The alternative schedule may not provide the same long-term protection as the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Banner University Medical Center - Tucson

    Tucson, Arizona, 85719, United States

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.